阿托伐他汀对糖尿病亚临床动脉粥样硬化的影响  

Effect of Atorvastatin on Diabetic Subclinical Atherosclerosis

作　　者：顾丽萍[1] 

机构地区：[1]武汉科技大学医院内科,湖北武汉430065

出　　处：《中国医药指南》2015年第23期7-8,共2页Guide of China Medicine

摘　　要：目的观察阿托伐他汀对糖尿病亚临床动脉粥样硬化患者颈动脉内中膜厚度(IMT)及血脂的影响。方法将100例糖尿病亚临床动脉粥样硬化患者随机分成二组,IMT≥0.9 mm,治疗组给以阿托伐他汀,20 mg/d临睡前口服,连续应用6个月,对照组给以非阿托伐他汀治疗,二组同时服用治疗糖尿病的药物,控制血糖。结果治疗组与对照组总胆固醇、三酰甘油、高、低密度脂蛋白水平及IMT比较有显据差异性(P<0.05)。结论阿托伐他汀可降低糖尿病亚临床动脉粥样硬化患者的血脂及IMT,可减缓亚临床动脉粥样硬化的发展。Objective To investigate the effect of atorvastatin on carotid artery intima-media thickness in diabetic subclinical atherosclerosis（IMT） and blood lipid. Methods 100 cases of subclinical atherosclerosis of diabetes patients were randomly divided into two groups, IMT≥0.9 mm, the group with treatment was given atorvastatin, 20 mg/d oral intake before bed, continuous application in June, the control group with non atorvastatin treatment, two groups at taking drugs to treat diabetes at the same time, to control glycemic. Resltus In the treatment group and the control group, total amount of cholesterol, triglyceride, high, low density lipoprotein level and IMT have significant difference（P 0.05）. Conclusion Atorvastatin can reduce blood lipids and IMT diabetic subclinical atherosclerosis in patients with slow, development of subclinical atherosclerosis.

关 键 词：亚临床动脉粥样硬化 阿托伐他汀 颈动脉内中膜厚度 糖尿病 

分 类 号：R587.1[医药卫生—内分泌]